CollPlant Biotechnologies has announced the expansion of the distribution network for its soft tissue repair matrix, VergenixSTR, in key European and Asian markets.
Designed to treat tendinopathy, VergenixSTR leverages the company’s recombinant human collagen (rhCollagen) technology to aid in the healing of various tendon injuries.
Go deeper with GlobalData
The company recently signed distribution agreements for the solution with partners in India, the Netherlands, and Turkey. They target sales in the territories of Belgium, Luxemburg (Benelux), Spain, Turkey, India, and the Netherlands.
The new Benelux and Spain distributor, with a background in orthopaedic medical device sales, received the first shipment from CollPlant this month.
Distributors in India and Turkey, both specialists in medical device distribution, are currently working with local regulatory bodies to begin sales of the product this year.
CollPlant Biotechnologies CEO Yehiel Tal said: “As we expand the distribution network in the Europe and Asia-Pacific regions, we are very excited to see the market potential for VergenixSTR. We look forward to taking additional steps this year to further expand our distribution network for VergenixSTR to other territories.”
VergenixSTR integrates cross-linked rhCollagen with platelet-rich plasma (PRP), enhancing the body’s natural healing processes, the company said.
This matrix supports cell growth and serves as a scaffold for the release of growth factors, essential for tissue regeneration and healing.
The product, injected into the injury site, forms a gel matrix that acts as a scaffold for cell growth and a reservoir for PRP, releasing growth factors to promote healing.
Leveraging its plant-based genetic engineering technology, CollPlant produces various rhCollagen-based products for medical applications.
Its product portfolio includes 3D bio-printed organs and tissues, medical aesthetics, and tissue repair solutions.
CollPlant secured a US patent in November 2023 for a photocurable dermal filler, further expanding its portfolio in the aesthetics market.
